DBV Technologies : Half year update on the DBV Technologies liquidity agreement

Accessibility: Skip TopNav

January 14, 2015 12:00 ET

DBV Technologies S.A.

DBV Technologies S.A.

Half year update on the DBV Technologies liquidity agreement

Bagneux, France, January 14, 2015 - Under the liquidity agreement signed between DBV TECHNOLOGIES and NATIXIS, the following resources were listed in the liquidity account on December 31st, 2014:

8 054 DBV TECHNOLOGIES' shares

As a reminder, during the last half year liquidity agreement on June 30th, 2014, the following assets appeared on the liquidity account:

9,018 DBV TECHNOLOGIES' shares

Under the terms of the liquidity contract, pursuant to Article 12, it is recalled that the following resources have been added as of December 15, 2014:

-                       EUR 600,000.00

It is specified that at the implementation of the said contract the following resources were listed in the liquidity account:

-                        0 titres DBV TECHNOLOGIES shares

-                        EUR 300,000.00

About DBV Technologies

DBV Technologies is developing Viaskin®, an innovative new approach to the treatment of allergies - a major public health issue that has been increasing in prevalence. DBV Technologies, incorporated in France in 2002, has developed a proprietary, worldwide-patented technology for administering an allergen to intact skin while avoiding transfer to the blood, and thus considerably lowering the risk of a systemic, allergic reaction in the event of accidental exposure. DBV Technologies is focusing on food allergies, including milk and peanut, for which there are currently no effective treatments. DBV Technologies has designed two products candidates: Viaskin® Peanut and Viaskin® Milk. The clinical development program for Viaskin® Peanut has received Fast Track designation from the US Food and Drug Administration.

DBV Technologies shares are traded on segment C of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345) and on the Nasdaq Stock Market in the form of American Depositary Shares (each representing one-half of one ordinary share) (Ticker: DBVT).

DBV Technologies Contacts

VP Finance, US Investor Relations & Strategy

Tel. : +1 917-346-3447

DBV IR and Media Contacts

Director, Corporate Communication & Business Development

Tel. : +33(0)1 55 42 78 72

U.S. Investor Relations

Tel. : +1 646-378-2926

Tel. : +1-212-223-4017